Psychedelic microdosing together with ADHD medication

by Team Inc.


Many people have turned to microdosing despite the uncertainties it brings. For example, it is used to relieve ADHD symptoms. However, there is an ongoing debate about whether MD's positive mental health outcomes are simply a placebo effect.

The practice of it has increased over the past five years microdosing of psilocybin mushrooms has skyrocketed in popularity. High-level executives, mothers and psilonauts continue to report improvements in mental health, creativity and focus, while clinical trials seek to validate the purported benefits.

Consuming small, sub-hallucinogenic doses appears to improve mindfulness and personality traits in adults with ADHD who struggle in these areas. The improvements persist even when people combine microdosing with conventional prescription medications. This means that one experiences the psychedelic benefits intertwined with the pharmaceutical reliability of medicines. A new approach.

Microdosing with ADHD

Most ADHD patients curb symptoms with drugs such as Adderall, Ritalin and Concerta. These medications reduce impulsivity and hyperactivity. However, in general, they do not help adults with ADHD tackle challenges such as being in the moment and not judging their sometimes negative thoughts. People with ADHD often struggle with emotional instability and negativity compared to their neurotypical counterparts. Medications can also cause anxiety and stress. From a psychedelic perspective, microdosing could offer people new options to manage the full breadth of symptoms.

New research shows results

The microdosing study, published in the Frontiers in Psychiatry Journal, collected data from 233 people using an online prospective naturalistic design. Most people had an ADHD diagnosis. The rest reported severe symptoms. About a third used ADHD medication daily.

During the study, most participants (77,8%) microdose psilocybin mushrooms or truffles with an average dose of 722 mg. Twelve took lysergamides (e.g., 1P-LSD, ALD-52) at a dose of 17,5 micrograms (μg), and the remainder consumed standard LSD at 12 μg.

The team speculates that there may be several factors that could have influenced the average dose, including possible interaction with meth diet substances such as Adderall, which could potentially influence the effects of a lower dose. In addition, factors such as psilocybin sensitivity and developed tolerance may also have played a role. It would be interesting to investigate more data on what affected the average dose. But let's get back to the study in question.

The study assessed mindfulness and personality traits at baseline and then two and four weeks after starting the protocol. Participants reported their experiences using validated measures.

Researchers hypothesized that microdosing would increase mindfulness, or being aware of and paying attention to thoughts, feelings, and sensations of the present moment without overreacting. They also thought microdosing would improve conscientiousness, extroversion, agreeableness, and openness while reducing neuroticism. Some results were consistent with the researcher's expectations. Others were surprising.

After four weeks, the participants with ADHD were more in line with general population averages. They showed more mindfulness, especially by acting consciously and not judging internal experiences. They also scored lower on neuroticism or emotional instability. After two weeks, participants taking conventional ADHD medication scored lower on mindfulness than the non-medicated cohort. However, four weeks of microdosing balanced the balance with equal improvements regardless of pharmaceutical use.

Furthermore, comorbid diagnoses, such as depression, anxiety and PTSD, did not affect overall progress. However, contrary to expectations, participants' personality traits such as friendliness and openness remained largely unchanged.

New treatment methods

The lack of change in personality raises questions about the ability of microdosing to have a meaningful impact on ADHD challenges. However, the results were still significant in several respects. First, they suggest that microdosing can induce changes in stable traits such as mindfulness and neuroticism.

Furthermore, the fact that ADHD medication did not affect these changes implies that microdosing could offer several therapeutic pathways that could build on the current treatment model. This discovery could enable more personalized treatment models, some of which involve a "both-and" approach, including traditional medicines and psychedelics.

The study is only a small step in providing the evidence. Nevertheless, it opens new avenues for exploring holistic approaches to managing ADHD. It also makes it clear that people have safe, experimental options that they may never have considered.

Source: (EN)

Related Articles

Leave a comment

[adrate banner="89"]